Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AstraZeneca launches pilot program for Cordio Medical’s AI heart failure app

By Sean Whooley | May 19, 2023

Cordio Medical HearO app

Cordio Medical’s HearO app analyzes the voice of heart failure patients to monitor their condition. [Photo courtesy of Cordio Medical]

AstraZeneca and the Bellvitge University Hospital plan to launch the first pilot program for the Cordio Medical HearO app.

The HearO smartphone app provides widespread access to medical-grade technology for patients with congestive heart failure (CHF). It enables the patient to monitor symptoms, manage treatment and improve quality of life.

Astrazeneca said the pilot program aims to assess the feasibility of using the app to monitor CHF patients. The monitoring takes place in both the hospital and at-home settings. It includes tracking HearO’s success rate of patient compliance and its ability to issue notices prior to heart failure events.

Get the full story at our sister site, Medical Design & Outsourcing.


Filed Under: Cardiovascular, Drug Discovery and Development
Tagged With: AstraZeneca, Cordio Medical
 

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Related Articles Read More >

AstraZeneca and U.S. government made a deal to lower drug prices for Americans
Sanofi ramps up distribution of Beyfortus ahead of RSV season
BMS
Label update broadens Camzyos reach in obstructive HCM, trims echo burden for stable patients
FDA logo
FDA drug approvals holding steady at 44 YTD in 2024
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE